On the one hand, the drug manufacturing industry is expanding, with an increase in global imports and exports. On the other hand however, the drug manufacturing industry is becoming more specialized.
A new analysis by Frost & Sullivan suggests companies in the health care industry can gain a...
Patheon has closed the transaction to acquire IRIX Pharmaceuticals, a company that specializes...
When it comes to the supply chain, business can be risky. A seminal survey of companies in various industries spanning 62 countries found 85% of respondents have experienced a supply chain disruption over the last 12 months, and 50% of companies had more than one disruption.
An environment of increasing risks, complex regulations and continuing cost pressures is impeding healthcare executives from moving quickly to seize untapped industry opportunities, according to the 7th annual UPS "Pain in the (Supply) Chain" survey.
In an increasingly complex and challenging climate, chemical companies are facing a combination of shifting market forces and an increasingly heterogeneous customer set. Many organizations are focusing solely on all-out growth or across-the-board cost-cutting strategies in an attempt to adjust course.
Our annual reader survey looks at issues facing innovator companies and the CMO/CSOs that support them.
Supply chain planning involves functions such as demand forecasting and planning, distribution inventory planning, and plant capacity planning and scheduling. The right mix of strategy, education, and systems can have a very high impact on a pharmaceutical manufacturer’s overall operations—and ultimately its bottom line.
An increase in the number of Internet pharmacies distributing pharmaceuticals to consumers online and heightened public scrutiny have led authorities to pay close attention to the issue of counterfeit medications. And already this year, the U.S. Food and Drug Administration (FDA) has issued a health care provider alert warning about an unapproved, counterfeit cancer medication that was distributed in the U.S.
DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai Inc., based in Woodcliff Lake, NJ, USA, for the production of sterile products. The agreement covers the production of eribulin mesylate as well as other developmental drugs.
Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending ApprovalsJuly 11, 2012 4:02 am | News | Comments
Tris Pharma, a specialty pharmaceutical company with fully integrated commercial manufacturing and drug development operations, announced today that in order to meet demand for its products (approved and near term) the company has fortified its supply chain, increased manufacturing capacity and strengthened its management team.
Today, ValueCentric was awarded the 2011 HDMA Distribution Management Award for their newest ValueTrak module, Safe & Secure Supply Chain. This award highlights new innovative business processes and the latest best practices in technology that improve the...
While recent attention has focused on issues such as the challenges associated with drug discovery and the regulatory review process, pharmaceutical companies have invested comparatively little effort in updating their manufacturing and distribution operations, many of which are inefficient, under-utilized and ill-equipped to cope with new medicines, cost pressures and health reform expectations
Keeping the Supply Chain Pure: New Coating Technologies Contain Information to Authenticate Solid Oral Dose PharmaceuticalsMay 7, 2010 10:08 am | by John D’Ottavio, Quality and Regulatory Affairs Manager, ARmark Authentication Technologies, LLC; and MaryAnn Hegedus, Business Development Manager, Colorcon, Inc. | Articles | Comments
A draft guidance recently issued by the Food and Drug Administration 1 provides specific recommendations for pharmaceutical manufacturers on the use of inks, pigments, flavors, and other molecular taggants used as physical-chemical identifiers (PCIDs) in immediate release film coatings for anticounterfeiting measures.
NSD Bio Group, LLC - North American Advisory firm, has been tapped by the U.S. China Economic and Security Review Commission, to conduct special research and analyses on the increasing role of China's raw ingredients used in pharmaceutical products and dietary supplements manufactured and sold in the U.S. marketplace.
At INTERPHEX, in March 2009, an expert panel convened to discuss the challenges facing the pharmaceutical industry in meeting the FDA's guidance regarding e-pedigree, and to address the larger global issues surrounding the implementation of RFID as part of a secure supply chain solution.
The pharmaceutical industry’s supply chain has become the focus of daily headlines, and often not in a positive way. Today’s pharmaceutical products rely on ingredients and material from across the globe, and require the tightest, safest, and most efficient supply chain possible to produce the highest quality drugs.